We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+11.77%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.63B
AUM Growth
-$1.1B
Cap. Flow
-$769M
Cap. Flow %
-21.2%
Top 10 Hldgs %
50.26%
Holding
130
New
22
Increased
12
Reduced
43
Closed
31

Top Buys

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$43.3M
2
PODD icon
Insulet
PODD
+$22.7M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$21.9M
4
SEPN
Septerna Inc
SEPN
+$17.7M
5
PEN icon
Penumbra
PEN
+$16.7M

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$88.3M
2
BHVN icon
Biohaven
BHVN
+$74.2M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$50.4M
4
APGE icon
Apogee Therapeutics
APGE
+$49.4M
5
APLT
Applied Therapeutics
APLT
+$44.8M

Sector Composition

Rank Sector Weight
1 Healthcare 98.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
51
Neurocrine Biosciences
NBIX
$18.2B
$13.7M 0.38%
100,050
-112,178
-53% -$13.9M
DYN icon
52
Dyne Therapeutics
DYN
$4.1B
$12.8M 0.35%
543,277
-174,867
-24% -$5.17M
XENE icon
53
Xenon Pharmaceuticals
XENE
$6.15B
$12.8M 0.35%
325,324
-199,606
-38% -$8.25M
MRUS
54
DELISTED
Merus
MRUS
$12.6M 0.35%
300,000
– –
CGON icon
55
CG Oncology
CGON
$6.07B
$12M 0.33%
419,450
-314,245
-43% -$10.8M
AVR
56
Anteris Technologies
AVR
$788M
$11.9M 0.33%
+2,140,000
New +$12M
EYPT icon
57
EyePoint Inc
EYPT
$988M
$11.5M 0.32%
1,537,274
+500,000
+48% +$4.65M
EW icon
58
Edwards Lifesciences
EW
$49.1B
$10.7M 0.3%
+145,000
New +$10.1M
TARS icon
59
Tarsus Pharmaceuticals
TARS
$2.52B
$10.3M 0.28%
186,662
-1,109,754
-86% -$50.4M
ADGM
60
Adagio Medical Holdings
ADGM
$9.55M
$10.3M 0.28%
9,812,419
– –
INSM icon
61
Insmed
INSM
$22.5B
$9.94M 0.27%
144,000
-36,000
-20% -$2.59M
CRNX icon
62
Crinetics Pharmaceuticals
CRNX
$8.88B
$9.43M 0.26%
184,525
-540,173
-75% -$30.2M
RAPT
63
DELISTED
RAPT Therapeutics
RAPT
$9.29M 0.26%
+735,000
New +$9.34M
OCUL icon
64
Ocular Therapeutix
OCUL
$1.84B
$9.21M 0.25%
1,078,495
-2,245,973
-68% -$21.9M
NARI
65
DELISTED
Inari Medical, Inc. Common Stock
NARI
$9.13M 0.25%
+178,797
New +$8.79M
OKUR
66
OnKure Therapeutics
OKUR
$160M
$8.64M 0.24%
+1,004,439
New +$15.2M
NRIX icon
67
Nurix Therapeutics
NRIX
$2.43B
$6.23M 0.17%
+330,614
New +$7.58M
ZBIO
68
Zenas BioPharma
ZBIO
$1.93B
$6.09M 0.17%
744,035
-400,000
-35% -$6.24M
IRTC icon
69
iRhythm Holdings
IRTC
$3.96B
$5.87M 0.16%
65,153
+42,562
+188% +$3.34M
RAPP
70
Rapport Therapeutics
RAPP
$1.96B
$5.53M 0.15%
311,551
-436,632
-58% -$9.68M
BBOT
71
BridgeBio Oncology
BBOT
$670M
$5.25M 0.14%
500,000
– –
RCKT icon
72
Rocket Pharmaceuticals
RCKT
$334M
$4.76M 0.13%
378,584
-553,267
-59% -$8.33M
CBLL
73
CeriBell Inc
CBLL
$676M
$4.67M 0.13%
+180,546
New +$4.92M
VERU icon
74
Veru
VERU
$35.2M
$4.22M 0.12%
648,316
-80,000
-11% -$594K
MREO
75
Mereo BioPharma
MREO
$49.8M
$3.8M 0.1%
1,085,512
+269,790
+33% +$1.06M
1 2
3
4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Perceptive Advisors held 130 positions worth $3.63B, down 23% from $4.73B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors withdrew a net $769M in Q4 2024, closing 31 positions and reducing 43 holdings. Its most notable exit was Biohaven, an estimated $74.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Janux Therapeutics worth $43.8M.

  • Perceptive Advisors's largest Q4 2024 buy was Janux Therapeutics: 817,895 shares worth $43.8M.
  • Perceptive Advisors added most to Insulet in Q4 2024, an estimated $22.7M increase.
  • Perceptive Advisors's biggest Q4 2024 reduction was Soleno Therapeutics, cutting an estimated $88.3M.
  • Perceptive Advisors fully exited Biohaven in Q4 2024, selling an estimated $74.2M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.63B portfolio in Q4 2024.
  • Perceptive Advisors opened 22 new positions and closed 31 in Q4 2024.
  • Perceptive Advisors's portfolio value fell 23% quarter-over-quarter to $3.63B.

Based on Perceptive Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.